Modeling interleukin-2-based immunotherapy in AIDS pathogenesis

8Citations
Citations of this article
30Readers
Mendeley users who have this article in their library.

Abstract

In this paper, we sought to identify the CD4+ T-cell dynamics in the course of HIV infection in response to continuous and intermittent intravenous courses of interleukin-2 (IL-2), the principal cytokine responsible for progression of CD4+ T-lymphocytes from the G1 to the S phase of the cell cycle. Based on multivariate regression models, previous literature has concluded that the increase in survival of CD4+ T-cell appears to be the critical mechanism leading to sustained CD4+ T-cell levels in HIV-infected patients receiving intermittent IL-2 therapy. Underscored by comprehensive mathematical modeling, a major finding of the present work is related to the fact that, rather than due to any increase in survival of CD4+ T-cells, the expressive, selective and sustained CD4+ T-cell expansions following IL-2 administration may be related to the role of IL-2 in modulating the dynamics of Fas-dependent apoptotic pathways, such as activation-induced cell death (AICD) or HIV-specific apoptotic routes triggered by viral proteins. © 2013 Elsevier Ltd.

Cite

CITATION STYLE

APA

Joly, M., & Odloak, D. (2013). Modeling interleukin-2-based immunotherapy in AIDS pathogenesis. Journal of Theoretical Biology, 335, 57–78. https://doi.org/10.1016/j.jtbi.2013.06.019

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free